Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients.
This study evaluated the relationship between serum levels of endogenous secretory receptor for advanced glycation endproducts (esRAGE) and coronary plaque progression in diabetic and nondiabetic patients. Serum esRAGE level was measured and quantitative coronary angiography (QCA) was performed in 265 consecutive patients at baseline and 1-year follow-up. Comparing to baseline, serum esRAGE level was significantly increased during follow-up in nondiabetic patients without plaque progression (p=0.014), unchanged in nondiabetic patients with plaque progression and diabetic patients without plaque progression, and decreased in diabetic patients with plaque progression (p=0.011). Moreover, change of esRAGE levels correlated with change of QCA measurements. Multivariable regression analyses revealed that high-density lipoprotein cholesterol (OR=0.214, p=0.037), hypertension (OR=2.755, p=0.011), high-sensitivity C-reactive protein (OR=1.083, p<0.001) and change of esRAGE (OR=23.477, p<0.001) were independent risk factors for plaque progression in diabetic patients. This study demonstrated an association of decreased serum esRAGE level with coronary plaque progression in patients with diabetes.